SA55 Injection Phase II Study in the Treatment of Mild/Moderate COVID-19 Patients
Phase 2
Recruiting
- Conditions
- Infection of Upper Respiratory Tract Caused by 2019-nCoV
- Interventions
- Drug: SA55 Injection
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Sinovac Life Sciences Co., Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT06042764
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China
Efficacy and Safety of SA58 Nasal Spray in Close Contact With COVID-19 People
Not Applicable
Active, not recruiting
- Conditions
- COVID-19
- Interventions
- Drug: PlaceboDrug: SA58 Nasal Spray
- First Posted Date
- 2022-12-29
- Last Posted Date
- 2023-01-12
- Lead Sponsor
- Sinovac Life Sciences Co., Ltd.
- Target Recruit Count
- 2900
- Registration Number
- NCT05667714
- Locations
- 🇨🇳
Beijing Ditan Hospital, Capital Medical University, Beijing, China
Efficacy and Safety of Anti-COVID-19 Antibody SA58 Nasal Spray to Prevent Infection in High-risk Populations
Not Applicable
Active, not recruiting
- Conditions
- COVID-19
- Interventions
- Drug: SA58 Nasal Spray
- First Posted Date
- 2022-12-27
- Last Posted Date
- 2023-01-12
- Lead Sponsor
- Sinovac Life Sciences Co., Ltd.
- Target Recruit Count
- 7000
- Registration Number
- NCT05664919
- Locations
- 🇨🇳
Inner Mongolia Fourth Hospital, Hohhot, The Inner Mongolia Autonomous Region, China
Immunogenicity and Safety of a Third Dose of COVID-19 Vaccine(Vero Cell), Inactivated in the Elderly
Phase 4
Completed
- Conditions
- COVID-19
- Interventions
- Biological: COVID-19 Vaccine (Vero cell), Inactivated
- First Posted Date
- 2022-06-01
- Last Posted Date
- 2022-08-11
- Lead Sponsor
- Sinovac Life Sciences Co., Ltd.
- Target Recruit Count
- 400
- Registration Number
- NCT05398926
- Locations
- 🇨🇳
Yongde Center for Diseases Control and Prevention, Lincang, Yunnan, China
Immunogenicity，Safety and Cross - Immune Response With Mutant Strains of a Third Dose of an Inactivated COVID-19 Vaccine
Phase 4
Active, not recruiting
- Conditions
- COVID-19
- Interventions
- Biological: Inactivated COVID-19 Vaccine
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Sinovac Life Sciences Co., Ltd.
- Target Recruit Count
- 180
- Registration Number
- NCT05329038
- Locations
- 🇨🇳
Rushan City Center for Disease Control and Prevention, Weihai, Shandong, China
Safety and Immunogenicity Study of Booster Vaccination in Different Doses of COVID-19 Vaccine (Vero Cell),Inactivated for Prevention of COVID-19
Phase 4
Completed
- Conditions
- COVID-19
- Interventions
- Biological: Medium-dose COVID-19 Vaccine(Vero Cell),InactivatedBiological: High-dosage of COVID-19 vaccine (Vero cell), Inactivated
- First Posted Date
- 2021-12-21
- Last Posted Date
- 2022-08-11
- Lead Sponsor
- Sinovac Life Sciences Co., Ltd.
- Target Recruit Count
- 340
- Registration Number
- NCT05165966
- Locations
- 🇨🇳
Beijing Youan Hospital Capital Medical University, Beijing, Beijing, China
Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine
Phase 1
Completed
- Conditions
- Pneumococcal Infections
- Interventions
- Biological: Investigational 13-valent Pneumococcal Polysaccharide Conjugate VaccineBiological: Control 13-valent Pneumococcal Polysaccharide Conjugate Vaccine ( WALVAX PCV13)Biological: Control 13-valent Pneumococcal Polysaccharide Conjugate Vaccine ( Pfizer PCV13)
- First Posted Date
- 2021-10-25
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Sinovac Life Sciences Co., Ltd.
- Target Recruit Count
- 310
- Registration Number
- NCT05092386
- Locations
- 🇨🇳
Henan Center for Diseases Control and Prevention, Zhengzhou, Henan, China
Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and Adolescents
Phase 4
Completed
- Conditions
- COVID-19
- Interventions
- Biological: Experimental Group
- First Posted Date
- 2021-08-05
- Last Posted Date
- 2023-09-25
- Lead Sponsor
- Sinovac Life Sciences Co., Ltd.
- Target Recruit Count
- 31041
- Registration Number
- NCT04992208
- Locations
- 🇨🇳
Yongping Center for Diseases Control and Prevention, Dali, Yunnan, China
Safety of an Inactivated SARS-CoV-2 Vaccine (CoronaVac) in Children and Adolescents
Phase 2
Completed
- Conditions
- COVID-19
- Interventions
- Biological: PlaceboBiological: SARS-CoV-2 Inactivated Vaccine
- First Posted Date
- 2021-05-13
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- Sinovac Life Sciences Co., Ltd.
- Target Recruit Count
- 500
- Registration Number
- NCT04884685
- Locations
- 🇨🇳
Zanhuang county Center for Disease Control and Prevention, Shijiazhuang, Hebei, China
Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection(COVID-19)
Phase 1
Completed
- Conditions
- COVID-19
- Interventions
- Biological: Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28Biological: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28Biological: Two doses of high dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28Biological: Two doses of placebo at the schedule of day 0,28
- First Posted Date
- 2020-05-12
- Last Posted Date
- 2022-08-11
- Lead Sponsor
- Sinovac Life Sciences Co., Ltd.
- Target Recruit Count
- 422
- Registration Number
- NCT04383574
- Locations
- 🇨🇳
Renqiu City Center for Disease Control and Prevention, Renqiu, Hebei, China
© Copyright 2025. All Rights Reserved by MedPath